Physostigmine and Restless Legs Syndrome
Peacock, Jeff M.D.; Mishra, Girish M.D.; Roy, Raymond C. M.D., Ph.D.*
To the Editor:
Restless legs syndrome (RLS) is a common neurologic disorder that uncommonly manifests in the perioperative period. Its anesthetic implications were recently discussed,1
but the reviewers did not reference a 2005 case report that described rapid relief of symptoms with physostigmine.3
Their perioperative recommendations for prevention and treatment were based on the current theory of causation involving dysfunctional central iron and dopamine metabolism and six case reports in which no patient experienced prompt resolution of symptoms. Oral administration of the dopamine D2/D3 receptor agonist, 0.125 mg pramipexole, produced relief after 30 min.4
We report the second case of prompt relief of RLS symptoms with intravenous physostigmine.
A 65-yr-old man presented for endoscopic ultrasound and fine needle aspiration of a submucosal gastric lesion. The patient met the international standard essential criteria for RLS: irresistible urge to move his legs, accompanied by unpleasant sensory complaints in his legs; increased agitation when the nursing staff insisted that he remain still; symptoms at home relieved by walking; and symptoms that are worse in the evening but reasonably controlled with dopamine D2/D3 receptor agonist therapy.1
His daily dose of pramipexole, extended-release 1.5 mg after dinner, was twice the maximum daily dose usually recommended for RLS6
and may reflect the severity of the syndrome. However, it is less than the average dose used to treat early Parkinson disease.7
His other comorbidities (medications) included obesity, obstructive sleep apnea, diabetes mellitus type 2 (insulin, metformin, glipizide), hypertension (lisinopril), coronary artery disease (aspirin, lovastatin), gastroesophageal reflux (omeprazole), and osteoarthritis (oxaprozin).
Anesthesia was provided with 2 mg midazolam, 440 mg propofol, and 10 mg ketamine intravenously (IV). He also received 4 mg ondansetron, 0.2 mg glycopyrrolate, and 20 mg IV esmolol and oxymetazoline intranasally before insertion of a nasopharyngeal airway. He was conversant on arrival in the recovery room. Within minutes he became agitated and tried to get off his stretcher to walk. He exhibited severe restlessness in both legs and complained of lower extremity tingling and tugging. The differential diagnoses in this setting included hypoxia (SpO2 98%), hypoglycemia (blood glucose 168 mg/dL), emergence delirium (conversant, oriented), neuroleptic-induced akathisia (no droperidol given), peripheral neuropathy, and a RLS flare (patient stated, “It’s my restless legs”). Administration of 1 mg IV physostigmine attenuated these symptoms within 3 min. Symptoms completely resolved with a second dose of 1 mg physostigmine. Five hours later, he was free of symptoms, despite not yet taking his usual evening dose of pramipexole.
It is difficult to reconcile this apparent effectiveness of physostigmine with the current view of the pathophysiology of RLS – central iron insufficiency altering the dopaminergic system with a decrease in the number of D2 receptors in the putamen, increased activity of tyrosine hydroxylase, and increased dopamine transporter density in the caudate, putamen, and striatum.1
But the cholinergic and dopaminergic systems do interact in certain brain regions, e.g.
, striatal cholinergic output is dopamine D2 receptor-mediated.10
In summary, two patients with acute manifestations of RLS syndrome obtained prompt sustained relief after administration of physostigmine. A clinical trial in the nonperioperative setting is needed to confirm this beneficial effect. A positive outcome could spur a different line of research into the mechanisms involved.
Jeff Peacock, M.D., Girish Mishra, M.D., Raymond C. Roy, M.D., Ph.D.
* *Wake Forest School of Medicine, Winston-Salem, North Carolina. firstname.lastname@example.org
1. Raux M, Karroum EG, Arnulf I. Case scenario: Anesthetic implications of restless legs syndrome. Anesthesiology. 2010;112:1511–7
2. Karroum EG, Raux M, Riou B, Arnulf I. [Acute exacerbation of restless legs syndrome during perioperative procedures: Case reports and suggested management]. Ann Fr Anesth Reanim. 2010;29:920–4
3. Alpert CC, Tobin DP, Dierdorf SF. Physostigmine for the acute treatment of restless legs syndrome. Anesth Analg. 2005;101:726–7
4. Smith P, White SM. Anaesthesia and restless legs syndrome. Eur J Anaesthesiol. 2009;26:89–90
5. Karroum EG, Golmard JL, Leu-Semenescu S, Arnulf I. Sensations in restless legs syndrome. Sleep Med. 2012;13:402–8
6. Högl B, Garcia-Borreguero D, Trenkwalder C, Ferini-Strambi L, Hening W, Poewe W, Brenner SS, Fraessdorf M, Busse M, Albrecht S, Allen RP. Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. Sleep Med. 2011;12:351–60
7. Hametner EM, Seppi K, Poewe W. Role and clinical utility of pramipexole extended release in the treatment of early Parkinson’s disease. Clin Interv Aging. 2012;7:83–8
8. Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders. Neurobiol Dis. 2012;46:1–18
9. Kim KW, Jhoo JH, Lee SB, Lee SD, Kim TH, Kim SE, Kim YK, Yoon IY. Increased striatal dopamine transporter density in moderately severe old restless legs syndrome patients. Eur J Neurol. 2012;19:1213–8
10. Ding YS, Logan J, Bermel R, Garza V, Rice O, Fowler JS, Volkow ND. Dopamine receptor-mediated regulation of striatal cholinergic activity: Positron emission tomography studies with norchloro[18F]fluoroepibatidine. J Neurochem. 2000;74:1514–21
This article has been cited 1 time(s).
Medical Journal of AustraliaRestless legs syndrome and day proceduresMedical Journal of Australia
© 2012 American Society of Anesthesiologists, Inc.
Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.